Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study

Journal of Clinical Psychiatry

Volumn 73, Issue 7, 2012, Pages 1002-1008

  Stein, Dan J ^a   Ahokas, Antti ^b   Albarran, Cristina ^c   Olivier, Valérie ^c   Allgulander, Christer ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Mehilainen Oy   (Finland)

^c IRIS Institut de Recherches Internationales Servier   (France)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; PLACEBO;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTONIA; FATIGUE; FEMALE; FINLAND; GASTROENTERITIS; GENERALIZED ANXIETY DISORDER; HUMAN; HUNGARY; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; SWEDEN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 84864403936     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07493     Document Type: Article

References (25)

1. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72-90. doi:10.102/da.20257 PubMed (Pubitemid 351213928)
2. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628-642. PubMed
3. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19(5):271-280. doi:10.1097/01.yic.0137184. 64610.c8 PubMed (Pubitemid 39141943)
4. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71(2):109-120. doi:10.408/JCP.09m05347blu PubMed
5. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24(6):479-499. doi:10.2165/153420-0-0 PubMed
6. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):561-566. doi:10.1097/JCP.0b013e318184f5b PubMed
7. Stocchi F, Nordera G, Jokinen RH, et al Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64(3):250-258. doi:10.408/JCP.v64n0305 PubMed (Pubitemid 36457322)
8. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9(5):495-505. doi:10.1017/S14614570505973 PubMed (Pubitemid 44607202)
9. Montgomery SA, Mahé V, Haudiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol. 2002;22(6):561-567. doi:10.1097/04714-202120-05 PubMed
10. Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010;67(12):1274-1281. doi:10.101/ archgenpsychiatry.2010.170 PubMed
11. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673-681. doi:10.1016/j.euroneuro.208.05.02 PubMed
12. Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18-28. doi:10.1097/YIC.0b013e3282f0f0d7 PubMed (Pubitemid 350294866)
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1/j.204-8341.1959.tb0467.x PubMed
14. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57. PubMed
15. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
16. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, 1976;217-222.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1/j.160-047.1983.tb09716.x PubMed (Pubitemid 13098606)
18. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95. doi:10.1097/04850-1960603-015 PubMed (Pubitemid 26373761)
19. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations-a review. Psychopharmacology (Berl). 1980;71(2):173-179. doi:10.107/BF043408 PubMed (Pubitemid 11254055)
20. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87. doi:10.1016/S06-323(98)0126-7 PubMed (Pubitemid 28305526)
21. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127. doi:10.159/069738 PubMed (Pubitemid 36469860)
22. Kobak KA, Kane JM, Thase ME, et al. Why do clinical trials fail? the problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27(1):1-5. doi:10.1097/JCP.0b013e31802eb4b7 PubMed (Pubitemid 46105756)
23. Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74(3):449-456. PubMed (Pubitemid 44285164)
24. Goodwin GM, Emsley R, Rembry S, et al Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(8):1128-1137. doi:10.408/JCP.08m04548 PubMed
25. EPAR. European Public Assessment Report - Valdoxan. EMEA/H/C/915 ed 2009.